ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.

Showing results for Advocacy

April 12, 2022

From April 4-8, U.S. members of the Association for Clinical Oncology (ASCO) participated in the 2022 ASCO Week of Action, which was held in conjunction with the Association’s annual Advocacy Summit. During the Week of Action, advocates from across the country sent a record 920 letters to Members of Congress through ASCO’s ACT Network urging them to take action on important policies to improve access to high-quality, equitable care for people with cancer.

April 7, 2022

The Association for Clinical Oncology (ASCO) presented its Advocate of the Year Award to Edward Balaban, DO, FACP, FASCO for his valuable contributions to ASCO’s advocacy efforts. The award recognizes volunteers who have gone above and beyond in the past year, advocating on behalf of patients and providers to improve cancer care and research. 

April 7, 2022

The Association for Clinical Oncology (ASCO) presented its Advocate of the Year Award to Edward Balaban, DO, FACP, FASCO for his valuable contributions to ASCO’s advocacy efforts. The award recognizes volunteers who have gone above and beyond in the past year, advocating on behalf of patients and providers to improve cancer care and research.

April 4, 2022

The Association for Clinical Oncology (ASCO) congratulates Dr. Norman E. “Ned” Sharpless on his successful tenure as Director of the National Cancer Institute (NCI). During his five years at NCI, Dr. Sharpless guided the Institute to advance the goals of the Cancer Moonshot Initiative, including important work to modernize cancer clinical trials to reflect an improved understanding of biology and the new types of therapies available to treat cancer. We are hopeful that these efforts will endure even after Dr. Sharpless’ departure later this month.

March 29, 2022

President Biden’s Fiscal Year (FY) 2023 budget request includes $5 billion for the Advanced Research Projects Agency for Health (ARPA-H), the proposed new biomedical research agency focused on high-risk, bold, translational research projects. While the Association for Clinical Oncology (ASCO) strongly believes in the stated mission of ARPA-H, we are concerned that the Administration’s FY 2023 budget request invests in ARPA-H at the expense of the National Institutes of Health (NIH) and the National Cancer Institute (NCI).

March 29, 2022

The Association for Clinical Oncology (ASCO) submitted comments to the Office of the National Coordinator for Health Information Technology (ONC) in response to the agency’s Request for Information (RFI) on electronic prior authorization (ePA).

March 17, 2022

Congress is considering several cancer policy priorities this week, including the PREVENT Pandemics Act, Cures 2.0, and legislation to authorize ARPA-H.

March 15, 2022

The Association for Clinical Oncology (ASCO) is holding its annual Advocacy Summit Week of Action from April 4-8, during which ASCO members are encouraged to connect with their Members of Congress about policies and legislation that impact cancer care and research.

March 11, 2022

The Fiscal Year 2022 omnibus funding bill provides $45 billion for the National Institutes of Health (NIH), including $6.9 billion for the NCI. The Association for Clinical Oncology (ASCO) commends Congress for their enthusiastic, bipartisan support for continued investment in biomedical research.

March 10, 2022

Members of the Regulatory Relief Coalition—including the Association for Clinical Oncology (ASCO)—participated in a week of action to call on Congress to pass the Improving Seniors’ Timely Access to Care Act (H.R. 3173/S. 3018).

March 9, 2022

The Centers for Medicare & Medicaid Services (CMS) announced that it will apply the Merit-based Incentive Payment System (MIPS) automatic extreme and uncontrollable circumstances (EUC) policy to all individual Merit-based Incentive Payment System (MIPS) eligible clinicians for the 2021 performance period.

March 7, 2022

The Association for Clinical Oncology (ASCO) submitted comments in response to the Centers for Medicare & Medicaid Services’ (CMS) Contract Year 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit Programs proposed rule. The rule proposes changes to advance the administration’s efforts to improve consumer protections, reduce disparities, and improve health equity in the MA and Part D programs.

March 1, 2022

The Association for Clinical Oncology (ASCO) sent a letter to members of the U.S. House of Representatives and U.S. Senate endorsing the Provider Relief Fund Improvement Act (H.R. 5963/S. 3611).

March 1, 2022

The Association for Clinical Oncology (ASCO), along with more than 20 other stakeholder groups, sent a letter to congressional leadership urging lawmakers in both chambers to pass legislation this year to help radiation therapy clinics continue to provide potentially life-saving care to patients with cancer.

March 1, 2022

The Association for Clinical Oncology (ASCO) joined with more than 100 organizations to urge Congress to support President Biden’s reinvigorated Cancer Moonshot and to allocate funding to support the initiative.

Pages